- Home
- FGEN vs PULM Comparison
FGEN vs PULM Comparison
Compare FGEN & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGEN
- PULM
- Stock Information
- Founded
- FGEN 1993
- PULM 2003
- Country
- FGEN United States
- PULM United States
- Employees
- FGEN N/A
- PULM N/A
- Industry
- FGEN Biotechnology: Pharmaceutical Preparations
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- FGEN Health Care
- PULM Health Care
- Exchange
- FGEN Nasdaq
- PULM Nasdaq
- Market Cap
- FGEN 33.5M
- PULM 20.5M
- IPO Year
- FGEN 2014
- PULM N/A
- Fundamental
- Price
- FGEN $7.03
- PULM $5.57
- Analyst Decision
- FGEN Strong Buy
- PULM
- Analyst Count
- FGEN 1
- PULM 0
- Target Price
- FGEN $250.00
- PULM N/A
- AVG Volume (30 Days)
- FGEN 43.0K
- PULM 10.9K
- Earning Date
- FGEN 08-12-2025
- PULM 08-12-2025
- Dividend Yield
- FGEN N/A
- PULM N/A
- EPS Growth
- FGEN N/A
- PULM N/A
- EPS
- FGEN N/A
- PULM N/A
- Revenue
- FGEN $6,996,000.00
- PULM $1,921,000.00
- Revenue This Year
- FGEN N/A
- PULM N/A
- Revenue Next Year
- FGEN N/A
- PULM $134.88
- P/E Ratio
- FGEN N/A
- PULM N/A
- Revenue Growth
- FGEN N/A
- PULM N/A
- 52 Week Low
- FGEN $4.50
- PULM $1.78
- 52 Week High
- FGEN $29.00
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- FGEN 50.17
- PULM 36.25
- Support Level
- FGEN $7.04
- PULM $5.20
- Resistance Level
- FGEN $7.56
- PULM $6.15
- Average True Range (ATR)
- FGEN 0.49
- PULM 0.30
- MACD
- FGEN -0.00
- PULM -0.05
- Stochastic Oscillator
- FGEN 12.53
- PULM 22.70
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).